Michael Zand – Page 247

News of Note—New data for Fate’s off-the-shelf CAR-T in ALL; Nektar tests BMS-partnered drug in immuno-oncology … – FierceBiotech

2018-04-16 Michael Zand NEWS

Immunotherapy-chemotherapy combination extends survival in … – Healio

Immunotherapy-chemotherapy combination extends survival in …HealioCHICAGO — The addition of the anti-PD-1 therapy pembrolizumab to chemotherapy significantly improved outcomes among patients with newly diagnosed metastatic nonsquamous non-small cell … Continue reading

2018-04-16 Michael Zand NEWS

Altered immune cells clear childhood brain tumor in mice – Stanford Medical Center Report

Stanford Medical Center ReportAltered immune cells clear childhood brain tumor in miceStanford Medical Center ReportIn mice whose brainstems were implanted with human DIPG, engineered immune cells known as chimeric antigen receptor T cells — or CAR-T c… Continue reading

2018-04-16 Michael Zand NEWS

Researchers Use Human Stem Cells to Repair Damaged Body Parts – Medical News Bulletin

Medical News BulletinResearchers Use Human Stem Cells to Repair Damaged Body PartsMedical News BulletinStem cell research possesses great potential for the advancement of medicine, therapy, and human health. Stem cells are undifferentiated cells capabl… Continue reading

2018-04-16 Michael Zand NEWS

Researchers Use Human Stem Cells to Repair Damaged Body Parts – Medical News Bulletin

2018-04-16 Michael Zand NEWS

CRISPR-Cas9 Improved 10000-Fold by Synthetic Nucleotides – Genetic Engineering & Biotechnology News

Genetic Engineering & Biotechnology NewsCRISPR-Cas9 Improved 10000-Fold by Synthetic NucleotidesGenetic Engineering & Biotechnology NewsScientists at the University of Alberta in Canada have developed a technology that can dramatically improve the spec… Continue reading

2018-04-16 Michael Zand NEWS

An off-the-shelf, dual-targeted CAR T-cell product shows promising results in preclinical studies – Medical Xpress

Medical XpressAn off-the-shelf, dual-targeted CAR T-cell product shows promising results in preclinical studiesMedical Xpress"We aimed to overcome these challenges by demonstrating proof-of-concept for an off-the-shelf, dual-targeted CAR T-cell ap… Continue reading

2018-04-16 Michael Zand NEWS

1
…
245
246
247
248
249
…
3,823

FierceBiotech

News of Note—New data for Fate’s off-the-shelf CAR–T in ALL; Nektar tests BMS-partnered drug in immuno-oncology …
FierceBiotech
Novartis’s FDA-approved CAR–T treatment for acute lymphoblastic leukemia (ALL), Kymriah, is personalized to individual patients and targets the surface antigen CD19. Fate Therapeutics has been working on an alternative to Kymriah that the company hopes …

Login

Cart

All posts by: Michael Zand

CRISPRdisco IDs, Annotates CRISPR Repeats, Cas Genes; Assembles Data in One Repository – GenomeWeb

News of Note—New data for Fate’s off-the-shelf CAR-T in ALL; Nektar tests BMS-partnered drug in immuno-oncology … – FierceBiotech

Immunotherapy-chemotherapy combination extends survival in … – Healio

Altered immune cells clear childhood brain tumor in mice – Stanford Medical Center Report

Researchers Use Human Stem Cells to Repair Damaged Body Parts – Medical News Bulletin

Researchers Use Human Stem Cells to Repair Damaged Body Parts – Medical News Bulletin

CRISPR-Cas9 Improved 10000-Fold by Synthetic Nucleotides – Genetic Engineering & Biotechnology News

An off-the-shelf, dual-targeted CAR T-cell product shows promising results in preclinical studies – Medical Xpress